First-in-Human: Simultaneous Hyperpolarized 1- 13 C-Pyruvate Magnetic Resonance Spectroscopy and 18 F-FDG PET (hyperPET) Imaging of a Patient With Lymphoma.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 39529265.
- Also identified by DOI 10.1097/RLU.0000000000005534.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hyperpolarized 1- 13 C-pyruvate magnetic resonance spectroscopy (MRS) and MRS imaging (MRSI) offer noninvasive and real-time direct assessment of the altered metabolism of cancer cells known as the Warburg effect-a key hallmark of cancer. When combined with simultaneously acquired 18 F-FDG PET in a PET/MR scanner, coined hyperPET by us, this dual-modality may unveil cancer-type specific glucose metabolic phenotypes with potential implications for patient prognostication, treatment-response assessment, and prediction. We here present the first human data of simultaneously acquired hyperpolarized MRS/MRSI and PET performed in a PET/MR scanner-and the first human hyperpolarized MRS/MRSI data from a patient with lymphoma.
Medical subject headings
- Fluorodeoxyglucose F18
- Lymphoma
- Positron-Emission Tomography
- Pyruvic Acid